Home/Pipeline/jCell (RPCs)

jCell (RPCs)

Diabetic Retinopathy

PreclinicalActive

Key Facts

Indication

Diabetic Retinopathy

Phase

Preclinical

Status

Active

Company

jCyte

About jCyte

jCyte is a private, pre-revenue biotech advancing a proprietary platform of retinal progenitor cell (RPC) therapies for inherited retinal diseases. Its lead asset, jCell, is in late-stage clinical development for retinitis pigmentosa, with a pivotal Phase 3 trial (JC02-88) now enrolling. The company leverages its RPC platform to pursue multiple ophthalmic indications, including diabetic retinopathy, positioning it in the high-need cell and gene therapy space for blindness. Leadership combines strong scientific co-founders with experienced biotech executives to drive clinical and corporate strategy.

View full company profile

Therapeutic Areas

Ophthalmology Retinal Diseases Genetic Disorders

Other Diabetic Retinopathy Drugs

Drug	Company	Phase	Status
Undisclosed Program (DR)	Cloudbreak Pharmaceutical	Pre-clinical / Clinical	In pipeline; uses ADS Platform
NOX4 Inhibitor (GLX7013114)	Glucox Biotech	Preclinical	Active
PER-001	Perfuse Therapeutics	Phase 2	Active
LumineticsCore	Digital Diagnostics	Approved	Active
Diabetic Retinopathy Program	Lxbio Pharmaceuticals	Pre-clinical	Active
Undisclosed	Hillhurst Biopharmaceuticals	Preclinical	Active
NBP-14 and derivatives	Neuro Bio	Research	Active
Vasculogenic Cell Therapy	Vascugen	Pre-clinical	Active
Danegaptide	Breye Therapeutics	Phase 2	Active
OcuRetina	Oculotix	Phase 2	Active
YH14618	Yuhan	Phase 2	Active